Ironwood Is Leading In GI Through Growth And Innovation

  • Leading position in the IBS-C / CIC market that exceeded $1 billion in 2021 LINZESS U.S. net sales, with continued strong prescription demand growth potential
  • Highly capable commercial team with deep GI experience across the U.S. with leading GI specialists and PCPs
  • Actively pursuing opportunities to strengthen innovative pipeline of GI assets in areas of high unmet need
  • Exploring linaclotide Lifecycle Management opportunities with potential pediatric FC indication in 6-17 year-olds in 2023
  • Strong balance sheet and cash flows enables disciplined capital allocation to reach new patients and to deliver value to shareholders
  • Accomplished management team with strong GI commercial, drug development and M&A expertise

Our Strategy:

Maximize LINZESS
Strengthen and Progress Innovative GI Portfolio
Deliver Sustained Profits and Generate Cash Flow